Amino acid compositions useful for increasing the amount of the divalent metal-ion transporter 1, DMT1 (encoded by the gene SLC11A2), on the duodenal bmsh border membrane (BBM) are described herein. Methods for increasing the concentration of DMT1 on the duodenal BBM (on trafficking) and increasing iron uptake are also presented. Compositions and methods described herein are useful for treating a disorder or disease associated with iron deficiency in subjects afflicted with such disorders or diseases. Use of these compositions for the treatment of disorders or diseases associated with iron deficiency and in the preparation of a medicament for the treatment of disorders or diseases associated with iron deficiency are also encompassed herein.

Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe.sup.2+ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.

An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

Described herein are methods of producing prebiotic compositions that are made up of oligosaccharide compositions, as well as methods of using such prebiotic compositions in nutritional compositions and methods of producing such oligosaccharide and nutritional compositions.

Provided herein is a nutritional supplement designed to support kidney and cardiac function as well as mitochondrial energy function needs in patients undergoing hemodialysis. This supplement replenishes essential vitamins and minerals that are lost during dialysis, does not contain compounds that may specifically cause harm to dialysis patients, and provides support for tissues undergoing oxidative stress.

A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of natural oil into a blend; milling said blend; optionally, heating the blend during the milling; and extracting a THCA-containing liquid generated during the milling.

The present invention pertains to a composition comprising a calcium source, a TRP agonist, water and optionally an excipient, wherein the amount of the calcium source is at least 5 wt %, based on the total weight of the composition.

The present invention pertains to a composition comprising a calcium source, a TRP agonist, water and optionally an excipient, wherein the amount of the calcium source is at least 5 wt %, based on the total weight of the composition.

The present invention aims to provide, for example, an oral composition containing reduced CoQ10 that exhibits reduced discoloration caused over time, that has high safety, and that is applicable to foods and drinks, a method for producing the same, and a method for reducing discoloration of a composition containing reduced CoQ10. The present invention relates to, for example, an oral composition containing reduced coenzyme Q10 and at least one sesamin compound, and having a mixing ratio by weight of the sesamin compound to the reduced coenzyme Q10 (sesamin compound/reduced coenzyme Q10) of 0.01 to 10.